Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 23, No 10 (April 1), 2005: pp. 2346-2357
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.00.240
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dudley, M. E.
Right arrow Articles by Rosenberg, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dudley, M. E.
Right arrow Articles by Rosenberg, S. A.

Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

Mark E. Dudley, John R. Wunderlich, James C. Yang, Richard M. Sherry, Suzanne L. Topalian, Nicholas P. Restifo, Richard E. Royal, Udai Kammula, Don E. White, Sharon A. Mavroukakis, Linda J. Rogers, Gerald J. Gracia, Stephanie A. Jones, David P. Mangiameli, Michelle M. Pelletier, Juan Gea-Banacloche, Michael R. Robinson, David M. Berman, Armando C. Filie, Andrea Abati, Steven A. Rosenberg

From the Surgery Branch; Experimental Immunology and Transplantation Branch; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute; National Eye Institute, National Institutes of Health, Bethesda, MD

Address reprint requests to Steven A. Rosenberg, MD, PhD, Surgery Branch, National Cancer Institute, NIH, CRC 3-3940, 10 Center Dr MSC 1201, Bethesda MD 20892-1202; e-mail: sar{at}mail.nih.gov

PURPOSE: We investigated the combination of lymphodepleting chemotherapy followed by the adoptive transfer of autologous tumor reactive lymphocytes for the treatment of patients with refractory metastatic melanoma.

PATIENTS AND METHODS: Thirty-five patients with metastatic melanoma, all but one with disease refractory to treatment with high-dose interleukin (IL) -2 and many with progressive disease after chemotherapy, underwent lymphodepleting conditioning with two days of cyclophosphamide (60 mg/kg) followed by five days of fludarabine (25 mg/m2). On the day following the final dose of fludarabine, all patients received cell infusion with autologous tumor-reactive, rapidly expanded tumor infiltrating lymphocyte cultures and high-dose IL-2 therapy.

RESULTS: Eighteen (51%) of 35 treated patients experienced objective clinical responses including three ongoing complete responses and 15 partial responses with a mean duration of 11.5 ± 2.2 months. Sites of regression included metastases to lung, liver, lymph nodes, brain, and cutaneous and subcutaneous tissues. Toxicities of treatment included the expected hematologic toxicities of chemotherapy including neutropenia, thrombocytopenia, and lymphopenia, the transient toxicities of high-dose IL-2 therapy, two patients who developed Pneumocystis pneumonia and one patient who developed an Epstein-Barr virus–related lymphoproliferation.

CONCLUSION: Lymphodepleting chemotherapy followed by the transfer of highly avid antitumor lymphocytes can mediate significant tumor regression in heavily pretreated patients with IL-2 refractory metastatic melanoma.

Authors' disclosures of potential conflicts of interest are found at the end of this article.




This article has been cited by other articles:


Home page
 BloodHome page
A. Boni, P. Muranski, L. Cassard, C. Wrzesinski, C. M. Paulos, D. C. Palmer, L. Gattinoni, C. S. Hinrichs, C.-C. Chan, S. A. Rosenberg, et al.
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers
Blood, December 1, 2008; 112(12): 4746 - 4754.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. F. Cheung, M. J.P. DuPage, H. K. Dong, J. Chen, and T. Jacks
Regulated Expression of a Tumor-Associated Antigen Reveals Multiple Levels of T-Cell Tolerance in a Mouse Model of Lung Cancer
Cancer Res., November 15, 2008; 68(22): 9459 - 9468.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. E. Dudley, J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. Robbins, J. Huang, D. E. Citrin, S. F. Leitman, et al.
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
J. Clin. Oncol., November 10, 2008; 26(32): 5233 - 5239.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Yan, N. Himoudi, M. Pule, N. Sebire, E. Poon, A. Blair, O. Williams, and J. Anderson
Development of Cellular Immune Responses against PAX5, a Novel Target for Cancer Immunotherapy
Cancer Res., October 1, 2008; 68(19): 8058 - 8065.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Q. Tang, B. Grzywacz, H. Wang, N. Kataria, Q. Cao, J. E. Wagner, B. R. Blazar, J. S. Miller, and M. R. Verneris
Umbilical Cord Blood T Cells Express Multiple Natural Cytotoxicity Receptors after IL-15 Stimulation, but Only NKp30 Is Functional
J. Immunol., October 1, 2008; 181(7): 4507 - 4515.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. A. de Witte, A. Jorritsma, A. Kaiser, M. D. van den Boom, M. Dokter, G. M. Bendle, J. B. A. G. Haanen, and T. N. M. Schumacher
Requirements for Effective Antitumor Responses of TCR Transduced T Cells
J. Immunol., October 1, 2008; 181(7): 5128 - 5136.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
R. Zappasodi, M. Di Nicola, C. Carlo-Stella, R. Mortarini, A. Molla, C. Vegetti, S. Albani, A. Anichini, and A. M. Gianni
The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells
Haematologica, October 1, 2008; 93(10): 1523 - 1534.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Weber
Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010)
Oncologist, October 1, 2008; 13(suppl_4): 16 - 25.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. M. Tatum, L. M. Mylin, S. J. Bender, M. A. Fischer, B. A. Vigliotti, M. J. Tevethia, S. S. Tevethia, and T. D. Schell
CD8+ T Cells Targeting a Single Immunodominant Epitope are Sufficient for Elimination of Established SV40 T Antigen-Induced Brain Tumors
J. Immunol., September 15, 2008; 181(6): 4406 - 4417.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. J. N. Cooper
Test-driving CARs
Blood, September 15, 2008; 112(6): 2172 - 2173.
[Full Text] [PDF]

Home page
 BloodHome page
B. G. Till, M. C. Jensen, J. Wang, E. Y. Chen, B. L. Wood, H. A. Greisman, X. Qian, S. E. James, A. Raubitschek, S. J. Forman, et al.
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Blood, September 15, 2008; 112(6): 2261 - 2271.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. A. Rosenberg
Overcoming obstacles to the effective immunotherapy of human cancer
PNAS, September 2, 2008; 105(35): 12643 - 12644.
[Full Text] [PDF]

Home page
 QJMHome page
J. King, J. Waxman, and H. Stauss
Advances in tumour immunotherapy
QJM, September 1, 2008; 101(9): 675 - 683.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Quintarelli, G. Dotti, B. De Angelis, V. Hoyos, M. Mims, L. Luciano, H. E. Heslop, C. M. Rooney, F. Pane, and B. Savoldo
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia
Blood, September 1, 2008; 112(5): 1876 - 1885.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
R. Bargou, E. Leo, G. Zugmaier, M. Klinger, M. Goebeler, S. Knop, R. Noppeney, A. Viardot, G. Hess, M. Schuler, et al.
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
Science, August 15, 2008; 321(5891): 974 - 977.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Menard, F. Ghiringhelli, S. Roux, N. Chaput, C. Mateus, U. Grohmann, S. Caillat-Zucman, L. Zitvogel, and C. Robert
CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?
Clin. Cancer Res., August 15, 2008; 14(16): 5242 - 5249.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. L. Kaufman, H.-J. Lenz, J. Marshall, D. Singh, C. Garett, C. Cripps, M. Moore, M. von Mehren, R. Dalfen, W. J. Heim, et al.
Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer
Clin. Cancer Res., August 1, 2008; 14(15): 4843 - 4849.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Wei, A. B. Shreiner, N. Takeshita, L. Chen, W. Zou, and A. E. Chang
Tumor-Induced Immune Suppression of In vivo Effector T-Cell Priming Is Mediated by the B7-H1/PD-1 Axis and Transforming Growth Factor {beta}
Cancer Res., July 1, 2008; 68(13): 5432 - 5438.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
O. J. Finn
Cancer Immunology
N. Engl. J. Med., June 19, 2008; 358(25): 2704 - 2715.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
K. R. Kalli, C. J. Krco, L. C. Hartmann, K. Goodman, M. J. Maurer, C. Yu, E. M. Johnson, C. L. Erskine, M. L. Disis, P. J. Wettstein, et al.
An HLA-DR-Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2-Specific Immunity in Patients with Cancer
Cancer Res., June 15, 2008; 68(12): 4893 - 4901.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Wallace, V. Kapoor, J. Sun, P. Mrass, W. Weninger, D. F. Heitjan, C. June, L. R. Kaiser, L. E. Ling, and S. M. Albelda
Transforming Growth Factor-{beta} Receptor Blockade Augments the Effectiveness of Adoptive T-Cell Therapy of Established Solid Cancers
Clin. Cancer Res., June 15, 2008; 14(12): 3966 - 3974.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. C. Palmer, C.-C. Chan, L. Gattinoni, C. Wrzesinski, C. M. Paulos, C. S. Hinrichs, D. J. Powell Jr., C. A. Klebanoff, S. E. Finkelstein, R. N. Fariss, et al.
From the Cover: Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity
PNAS, June 10, 2008; 105(23): 8061 - 8066.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
P. C. Tumeh, C. G. Radu, and A. Ribas
PET Imaging of Cancer Immunotherapy
J. Nucl. Med., June 1, 2008; 49(6): 865 - 868.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Z. Sebestyen, E. Schooten, T. Sals, I. Zaldivar, E. San Jose, B. Alarcon, S. Bobisse, A. Rosato, J. Szollosi, J. W. Gratama, et al.
Human TCR That Incorporate CD3{zeta} Induce Highly Preferred Pairing between TCR{alpha} and {beta} Chains following Gene Transfer
J. Immunol., June 1, 2008; 180(11): 7736 - 7746.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. K. Darcy
IL-21 priming enhances T-cell immunotherapy
Blood, June 1, 2008; 111(11): 5268 - 5269.
[Full Text] [PDF]

Home page
 BloodHome page
C. S. Hinrichs, R. Spolski, C. M. Paulos, L. Gattinoni, K. W. Kerstann, D. C. Palmer, C. A. Klebanoff, S. A. Rosenberg, W. J. Leonard, and N. P. Restifo
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
Blood, June 1, 2008; 111(11): 5326 - 5333.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Coccoris, E. Swart, M. A. de Witte, J. W. J. van Heijst, J. B. A. G. Haanen, K. Schepers, and T. N. M. Schumacher
Long-Term Functionality of TCR-Transduced T Cells In Vivo
J. Immunol., May 15, 2008; 180(10): 6536 - 6543.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Kline, I. E. Brown, Y.-Y. Zha, C. Blank, J. Strickler, H. Wouters, L. Zhang, and T. F. Gajewski
Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma
Clin. Cancer Res., May 15, 2008; 14(10): 3156 - 3167.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Maury, C. Cordonnier, M. Kuentz, D. Klatzmann, and J. L. Cohen
Searching for factors to improve the antileukemic effect of donor lymphocyte infusion
Blood, May 15, 2008; 111(10): 5256 - 5256.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
O. Goldberger, I. Volovitz, A. Machlenkin, E. Vadai, E. Tzehoval, and L. Eisenbach
Exuberated Numbers of Tumor-Specific T Cells Result in Tumor Escape
Cancer Res., May 1, 2008; 68(9): 3450 - 3457.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
J. Schlom, J. L. Gulley, and P. M. Arlen
Paradigm Shifts in Cancer Vaccine Therapy
Experimental Biology and Medicine, May 1, 2008; 233(5): 522 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Worschech, M. Kmieciak, K. L. Knutson, H. D. Bear, A. A. Szalay, E. Wang, F. M. Marincola, and M. H. Manjili
Signatures Associated with Rejection or Recurrence in HER-2/neu-Positive Mammary Tumors
Cancer Res., April 1, 2008; 68(7): 2436 - 2446.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Jorritsma, A. D. Bins, T. N.M. Schumacher, and J. B.A.G. Haanen
Skewing the T-Cell Repertoire by Combined DNA Vaccination, Host Conditioning, and Adoptive Transfer
Cancer Res., April 1, 2008; 68(7): 2455 - 2462.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Machlenkin, R. Uzana, S. Frankenburg, G. Eisenberg, L. Eisenbach, J. Pitcovski, R. Gorodetsky, A. Nissan, T. Peretz, and M. Lotem
Capture of Tumor Cell Membranes by Trogocytosis Facilitates Detection and Isolation of Tumor-Specific Functional CTLs
Cancer Res., March 15, 2008; 68(6): 2006 - 2013.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Fujita, X. Zhu, K. Sasaki, R. Ueda, K. L. Low, I. F. Pollack, and H. Okada
Inhibition of STAT3 Promotes the Efficacy of Adoptive Transfer Therapy Using Type-1 CTLs by Modulation of the Immunological Microenvironment in a Murine Intracranial Glioma
J. Immunol., February 15, 2008; 180(4): 2089 - 2098.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Mirmonsef, G. Tan, G. Zhou, T. Morino, K. Noonan, I. Borrello, and H. I. Levitsky
Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation
Blood, February 15, 2008; 111(4): 2112 - 2121.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
A. B. Heimberger, W. Sun, S. F. Hussain, M. Dey, L. Crutcher, K. Aldape, M. Gilbert, S. J. Hassenbusch, R. Sawaya, B. Schmittling, et al.
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study
Neuro-oncol, February 1, 2008; 10(1): 98 - 103.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. A. Marques, P. S. Hahnel, C. Wolfel, S. Thaler, C. Huber, M. Theobald, and M. Schuler
An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression
Blood, February 1, 2008; 111(3): 1413 - 1419.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Barber, T. Zhang, and C. L. Sentman
Immunotherapy with Chimeric NKG2D Receptors Leads to Long-Term Tumor-Free Survival and Development of Host Antitumor Immunity in Murine Ovarian Cancer
J. Immunol., January 1, 2008; 180(1): 72 - 78.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Jorritsma, R. Gomez-Eerland, M. Dokter, W. van de Kasteele, Y. M. Zoet, I. I. N. Doxiadis, N. Rufer, P. Romero, R. A. Morgan, T. N. M. Schumacher, et al.
Selecting highly affine and well-expressed TCRs for gene therapy of melanoma
Blood, November 15, 2007; 110(10): 3564 - 3572.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. H. Yi, H. Nechushtan, W. J. Bowers, G. R. Walker, Y. Zhang, D. G. Pham, E. R. Podack, H. J. Federoff, K. A. Tolba, and J. D. Rosenblatt
Adoptively Transferred Tumor-Specific T Cells Stimulated Ex vivo Using Herpes Simplex Virus Amplicons Encoding 4-1BBL Persist in the Host and Show Antitumor Activity In vivo
Cancer Res., October 15, 2007; 67(20): 10027 - 10037.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
J. N. Kochenderfer and R. E. Gress
A Comparison and Critical Analysis of Preclinical Anticancer Vaccination Strategies
Experimental Biology and Medicine, October 1, 2007; 232(9): 1130 - 1141.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
R. M. Wong, R. R. Scotland, R. L. Lau, C. Wang, A. J. Korman, W. M. Kast, and J. S. Weber
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
Int. Immunol., October 1, 2007; 19(10): 1223 - 1234.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. K. Choi, Y. H. Kim, W. J. Kang, S. K. Lee, K. H. Kim, S. M. Shin, W. M. Yokoyama, T. Y. Kim, and B. S. Kwon
Mechanisms Involved in Synergistic Anticancer Immunity of Anti-4-1BB and Anti-CD4 Therapy
Cancer Res., September 15, 2007; 67(18): 8891 - 8899.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Lizee, M. A. Cantu, and P. Hwu
Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy
Clin. Cancer Res., September 15, 2007; 13(18): 5250 - 5255.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell
Transforming Growth Factor-{beta} and the Immune Response: Implications for Anticancer Therapy
Clin. Cancer Res., September 15, 2007; 13(18): 5262 - 5270.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. M. Paulos, A. Kaiser, C. Wrzesinski, C. S. Hinrichs, L. Cassard, A. Boni, P. Muranski, L. Sanchez-Perez, D. C. Palmer, Z. Yu, et al.
Toll-like Receptors in Tumor Immunotherapy
Clin. Cancer Res., September 15, 2007; 13(18): 5280 - 5289.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. F. McDermott and M. B. Atkins
More Support for the Judicious Use of High-Dose Interleukin-2 in Patients With Advanced Melanoma
J. Clin. Oncol., September 1, 2007; 25(25): 3791 - 3793.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Mizukami, T. Hanagiri, M. Yasuda, K. Kuroda, Y. Shigematsu, T. Baba, T. Fukuyama, Y. Nagata, T. So, Y. Ichiki, et al.
Antitumor Effect of Antibody against a SEREX-Defined Antigen (UOEH-LC-1) on Lung Cancer Xenotransplanted into Severe Combined Immunodeficiency Mice
Cancer Res., September 1, 2007; 67(17): 8351 - 8357.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Matter, V. Pavelic, D. D. Pinschewer, S. Mumprecht, B. Eschli, T. Giroglou, D. von Laer, and A. F. Ochsenbein
Decreased Tumor Surveillance after Adoptive T-Cell Therapy
Cancer Res., August 1, 2007; 67(15): 7467 - 7476.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. J. Pittet, J. Grimm, C. R. Berger, T. Tamura, G. Wojtkiewicz, M. Nahrendorf, P. Romero, F. K. Swirski, and R. Weissleder
In vivo imaging of T cell delivery to tumors after adoptive transfer therapy
PNAS, July 24, 2007; 104(30): 12457 - 12461.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Schlom, P. M. Arlen, and J. L. Gulley
Cancer Vaccines: Moving Beyond Current Paradigms
Clin. Cancer Res., July 1, 2007; 13(13): 3776 - 3782.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Hsu, S. A. Jones, C. J. Cohen, Z. Zheng, K. Kerstann, J. Zhou, P. F. Robbins, P. D. Peng, X. Shen, T. J. Gomes, et al.
Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene
Blood, June 15, 2007; 109(12): 5168 - 5177.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. M. Curtsinger, M. Y. Gerner, D. C. Lins, and M. F. Mescher
Signal 3 Availability Limits the CD8 T Cell Response to a Solid Tumor
J. Immunol., June 1, 2007; 178(11): 6752 - 6760.
[Abstract] [Full Text] [PDF]